Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma

Annals of Nuclear Medicine

Volumn 18, Issue 4, 2004, Pages 345-349

  Kita, Tamotsu ^a,c   Yokoyama, Kunihiko ^a   Higuchi, Takahiro ^b   Kinuya, Seigo ^a   Taki, Junichi ^a   Nakajima, Kenichi ^a   Michigishi, Takatoshi ^a   Tonami, Norihisa ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA CARDIOVASCULAR HOSPITAL   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Dose; Radioiodine therapy; Short term side effects; Thyroid cancer; TSH

Indexed keywords

DOMPERIDONE; IODINE 131; LEVOTHYROXINE; RADIOACTIVE IODINE; RAMOSETRON; THYROTROPIN;

ADOLESCENT; ADULT; AGE; AGED; ANOREXIA; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; NECK DISSECTION; PAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALIVARY GLAND DISEASE; SEX DIFFERENCE; TASTE DISORDER; THYROID CARCINOMA; THYROIDECTOMY; VOMITING;

EID: 4143103463     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984474     Document Type: Article

References (10)

1. Van Nostrand D, Neutze J, Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 1986; 27: 1519-1527.
2. Lin W, Shen YY, Wang SJ. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 1996; 21: 780-782.
3. Mazzaferri EL. Radioiodine and other treatments and outcome. In: Werner and Ingbar's the Thyroid, Braverman L, Utiger RD (eds), Philadelphia; Lippincott-Raven Publishers, 1996: 922-945.
4. Zettinig G, Hanselmayer G, Fueger BJ, Hofmann A, Pirich C, Nepp J, et al. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med 2002; 29: 1428-1432.
5. Bohuslavizki KH, Brenner W, Klutmann S, Hubner RH, Lassmann S, Feyerabend B, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J Nucl Med 1998; 39: 1237-1242.
6. Solans R, Bosch JA, Galofre P, Porta F, Rosello J, Selva-O'Callagan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001; 42: 738-743.
7. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radio-iodine therapy for thyroid carcinoma. J Nucl Med 1998; 39: 1551-1554.
8. Levy HA, Park CH. Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer. Clin Nucl Med 1987; 12: 303-307.
9. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endcrinol Metab 1994; 78: 188-196.
10. Krausz Y, Uziely B, Nesher R, Chisin R, Glaser B. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer. Isr Med Assoc 2001; 11: 843-849.